Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Cheli

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Pharmacogenomics Journal|February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
International Journal of Molecular Sciences|May 7, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic CohortMarco Schiuma, Sofia Dinegro, Vera Battini, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2019
ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary studyBeatrice De Troia, Davide Dalu, Virginio Filipazzi, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Pharmacogenomics Journal|February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
International Journal of Molecular Sciences|May 7, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic CohortMarco Schiuma, Sofia Dinegro, Vera Battini, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2019
ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary studyBeatrice De Troia, Davide Dalu, Virginio Filipazzi, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Pageof 5